CUMBERLAND PHARMACEUTICALS INC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Nashville,, TN
SEC filing record 1 source field available
Fiscal year end
31 December
CUMBERLAND PHARMACEUTICALS INC has filed 1,032 SEC EDGAR filings since 02 May 2002

SEC filing history

Showing 526-550 of 959 matching filings.

Per page
25
Current page
22
3

FORM 3 SUBMISSION

Filing date
28 Sep 2018
Reporting date
19 Sep 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-33637

8-K 5.02 NEW DIRECTOR

Filing date
21 Sep 2018
Reporting date
21 Sep 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
31 Aug 2018
Reporting date
28 Aug 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
31 Aug 2018
Reporting date
30 Aug 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-33637

8-K

Filing date
14 Aug 2018
Reporting date
14 Aug 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-33637

8-K

Filing date
03 Aug 2018
Reporting date
03 Aug 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-33637

8-K INVESTOR PRESENTATION JUNE 2018

Filing date
01 Jun 2018
Reporting date
01 Jun 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
18 May 2018
Reporting date
17 May 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
10-Q File 001-33637

10-Q Q1 2018

Filing date
09 May 2018
Reporting date
31 Mar 2018
Next action
Verify source filing
8-K File 001-33637

8-K Q1 2018 EARNINGS RELEASE

Filing date
08 May 2018
Reporting date
08 May 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-33637

8-K - APRIL 2018 - VOTE OF ANNUAL SH MEETING

Filing date
27 Apr 2018
Reporting date
27 Apr 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-33637

8-K - CUMBERLAND ONCOLOGY

Filing date
13 Apr 2018
Reporting date
13 Apr 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-33637

8-K - H. PYLORI PUBLICATION

Filing date
30 Mar 2018
Reporting date
30 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
23 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
23 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
23 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
23 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
23 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
23 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
23 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
23 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
23 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
23 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
19 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .